Health Technology AnGes, Inc. Business Summary
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.
Financial Highlights
Dec 2022
JPY USD Revenue 67.06M 0.50M Gross Profit -2,920.27M -22.20M Operating income -16,316.80M -124.05M Income before tax -14,716.99M -111.89M Net income -14,714.77M -111.87M EBITDA -13,414.97M -101.99M Diluted EPS -94.29 -0.71 Dividends Per Share 0 0 Total Assets 38,820.71M 294.21M Total liabilities 8,395.30M 63.62M Total equity 30,425.40M 230.59M Operating cash flow -11,214.24M -85.26M Currency in JPY Currency in USD
Historical Data Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Revenue
610.05M
326.75M
39.99M
64.14M
67.06M
Gross Profit
418.87M
235.16M
12.06M
-2,410.09M
-2,920.27M
Operating income
-3,065.25M
-3,270.00M
-5,599.39M
-15,632.08M
-16,316.80M
Income before tax
-3,003.00M
-3,751.60M
-4,204.95M
-13,735.29M
-14,716.99M
Net income
-2,996.62M
-3,750.82M
-4,209.51M
-13,675.58M
-14,714.77M
EBITDA
-3,057.39M
-3,262.68M
-5,591.80M
-13,206.00M
-13,414.97M
Diluted EPS
-34.46
-35.81
-35.32
-92.85
-94.29
Dividends Per Share
0
0
0
0
0
Total Assets
8,050.67M
12,524.60M
38,354.61M
45,455.74M
38,820.71M
Total liabilities
316.21M
469.24M
5,674.93M
6,821.00M
8,395.30M
Total equity
7,734.45M
12,055.35M
32,679.67M
38,634.74M
30,425.40M
Operating cash flow
-2,522.50M
-2,179.91M
-2,961.32M
-11,380.54M
-11,214.24M
Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Revenue
5.52M
2.99M
0.37M
0.58M
0.50M
Gross Profit
3.79M
2.15M
0.11M
-21.93M
-22.20M
Operating income
-27.75M
-29.99M
-52.44M
-142.27M
-124.05M
Income before tax
-27.19M
-34.41M
-39.38M
-125.01M
-111.89M
Net income
-27.13M
-34.40M
-39.42M
-124.46M
-111.87M
EBITDA
-27.68M
-29.92M
-52.37M
-120.19M
-101.99M
Diluted EPS
-0.31
-0.32
-0.33
-0.84
-0.71
Dividends Per Share
0
0
0
0
0
Total Assets
73.37M
115.24M
371.49M
394.73M
294.21M
Total liabilities
2.88M
4.31M
54.96M
59.23M
63.62M
Total equity
70.49M
110.93M
316.52M
335.50M
230.59M
Operating cash flow
-22.83M
-19.99M
-27.73M
-103.57M
-85.26M
Valuation Measures
Dec 2022
PER -- ROA -34.92% ROE -42.61% Operating margin -24,331.28% Profit margin -21,942.36%
Key executives
President & Representative Director:
Ei Yamada
Director, Executive Officer & Manager-Finance:
Tetsuji Yoneo
Director & Manager-Drug Discovery Research:
Kazuo Suzuki
Executive Officer, Manager-R&D Promotion:
Hajime Watanabe
Manager-Accounting:
Jun Sakurai Shareholders
Shionogi & Co., Ltd. (0.6%)
HAYASHI YUICHIRO (0.6%)
KAWAI HIROSHI /SAKAI/ (0.3%)
MORISHITA RYUICHI (0.3%)
Dimensional Fund Advisors LP (0.1%)
Siemens Fonds Invest GmbH (0.0%)
SSgA Funds Management, Inc. (0.0%)
UBS Asset Management (UK) Ltd. (0.0%)
SPARX Asset Management Co., Ltd. (0.0%)
Mercer Global Investments Europe Ltd. (0.0%)
Contact Details Website: http://www.anges.co.jp Address:
Saito Bio-Incubator, 1/F,
7-7-15 Saito-Asagi,
Osaka,
567-0085,
Japan
Phone:
+81.72.643.3590
Related Companies
Emendo Biotherapeutics, Inc.
AnGes USA, Inc.
AnGes Euro Ltd.
Competitors
Athira Pharma, Inc.
Editas Medicine, Inc.
Sienna Biopharmaceuticals, Inc.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 29 May, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close